Polaryx Secures FDA Fast Track for PLX-200 in Four Rare LSD Indications
Polaryx Therapeutics has secured FDA Fast Track Designation for its PLX-200 candidate across all four indications—CLN2, CLN3, Krabbe and Sandhoff diseases—qualifying it for expedited review and rolling submissions. The designation covers the full SOTERIA Phase 2 basket trial, set to start in the second half of 2026 in the US, Europe and Asia.
1. FDA Grants Fast Track Designations
The FDA has granted Fast Track Designation to PLX-200 for Juvenile Neuronal Ceroid Lipofuscinosis (CLN3), Krabbe disease and Sandhoff disease, adding to the March award for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) so that all four indications in the SOTERIA basket trial now carry this status.
2. Benefits of Fast Track for PLX-200
Fast Track status allows for more frequent interactions with the FDA and the potential for rolling review of a future marketing application, which may accelerate the regulatory path and reduce development risk for PLX-200.
3. SOTERIA Phase 2 Basket Trial Details
SOTERIA is an open-label, single-arm Phase 2 trial designed to assess safety, tolerability and clinical activity of PLX-200 in the four lysosomal storage diseases, with planned initiation in the second half of 2026 across trial sites in the United States, Europe and Asia.
4. PLX-200 Profile and Market Opportunity
PLX-200 is an oral gemfibrozil-based compound shown to cross the blood–brain barrier, targeting an estimated one quarter of the global lysosomal storage disease population and addressing critical unmet needs in rare pediatric neurodegenerative disorders.